Skip to main content
ASKA Pharmaceutical Holdings CO., Ltd. logo

ASKA Pharmaceutical Holdings CO., Ltd. — Investor Relations & Filings

Ticker · 4886 ISIN · JP3119660003 T Manufacturing
Open in API
Filings indexed 48 across all filing types
Latest filing 2026-05-25 Regulatory Filings
Country JP Japan
Listing T 4886

About ASKA Pharmaceutical Holdings CO., Ltd.

https://www.aska-pharma.co.jp/english/

ASKA Pharmaceutical Holdings Co., Ltd. is a healthcare group engaged in the research, development, manufacturing, and sale of pharmaceuticals. The company specializes in hormone-related medicines, with a primary focus on three therapeutic areas: internal medicine, obstetrics and gynecology, and urology. It is a leading provider of treatments for thyroid disease. The product portfolio includes various hormone preparations, such as the emergency contraceptive pill NORLEVO® and leuprorelin acetate for injection, used in treating conditions like prostate cancer and endometriosis. The group actively pursues the creation of innovative products, including new antibody drugs, through research and development collaborations to meet evolving medical needs.

Recent filings

Filing Released Lang Actions
臨時報告書
Regulatory Filings Classification · 85% confidence The document is a Japanese 臨時報告書 (“timely report”) filed under the Financial Instruments and Exchange Act to disclose a change in the company’s audit firm (公認会計士等). This is a statutory regulatory disclosure rather than an Annual or Interim Report, Earnings Release, or any other specific financial report. It serves as a regulatory announcement of auditor appointment/retirement. Under the provided taxonomy, such a miscellaneous compliance filing falls under Regulatory Filings (RNS).
2026-05-25 Japanese
ダルトンらによる大規模買付行為等が企図されている現状（有事）を踏まえたダルトンらが当社の対応方針を遵守せず大規模買付行為等を行った場合における
Proxy Solicitation & Information Statement Classification · 60% confidence The document is an official company announcement detailing the board’s resolution to submit a specific proposal at the upcoming Annual General Meeting (AGM) for shareholder approval of potential defensive countermeasures. It is neither a full annual or interim report, nor a simple press release about report publication. Rather, it provides substantive materials to shareholders ahead of a voting process—i.e., information and rationale for the AGM proposal—which aligns with our Proxy Solicitation & Information Statement category.
2026-05-25 Japanese
公認会計士等の異動に関するお知らせ
Regulatory Filings Classification · 82% confidence The document is a corporate announcement under Japan’s Financial Instruments and Exchange Act regarding the upcoming change in the company’s public accounting firm (audit firm) and the resolution to propose this change at the next shareholder meeting. It does not contain actual financial statements or audit opinions themselves, nor is it a presentation, proxy, or earnings release. It is a general regulatory announcement of auditor appointment, best classified under Regulatory Filings (RNS) as a miscellaneous compliance notice.
2026-05-25 Japanese
取締役（社外取締役及び監査等委員である取締役を除く）に対する譲渡制限付株式報酬制度の改定及び社外取締役（監査等委員である取締役を除く）に対する譲渡
Proxy Solicitation & Information Statement Classification · 82% confidence The document is a Japanese corporate announcement detailing proposed amendments to the restricted share remuneration plan for directors and the introduction of a new plan for outside directors, to be voted on at the upcoming Ordinary General Meeting. It is not the full AGM materials presented at the meeting (AGM-R), nor is it a results announcement or financial report. Instead, it provides shareholders with information about agenda items and solicits their approval, matching the definition of a proxy solicitation/information statement. Therefore, this matches category PSI.
2026-05-25 Japanese
定款一部変更に関するお知らせ
Proxy Solicitation & Information Statement Classification · 75% confidence The document is a corporate announcement titled “定款一部変更に関するお知らせ” (“Notice of Partial Amendments to the Articles of Incorporation”) informing shareholders of proposals to be submitted at the upcoming Annual General Meeting (AGM), including the purpose and text of the amendments and meeting date. It is not the full AGM materials or minutes but rather the proxy information sent to shareholders to explain and solicit votes on agenda items. This matches the definition for Proxy Solicitation & Information Statement (PSI).
2026-05-25 Japanese
（訂正・数値データ訂正）「2026年3月期 決算短信〔日本基準〕（連結）」の一部訂正について
Earnings Release Classification · 90% confidence The document is titled “2026年3月期 決算短信〔日本基準〕” (financial results summary) and contains the initial full‐year earnings announcement including summary consolidated financial statements and forecasts. It is not a full audited annual report (10-K) nor a regulatory filing announcing publication of a report, but the company’s earnings release (“決算短信”) for the fiscal year ended March 2026. Therefore, it should be classified as an Earnings Release (ER). FY 2026
2026-05-19 Japanese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.